EXCLUSIVE PATENT LICENSE AGREEMENT by and between MERCK, SHARP & DOHME CORPORATION and TARGENICS, Inc.Exclusive Patent License Agreement • November 22nd, 2017 • ARMO BioSciences, Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”), dated as of December 12, 2012 (the “Effective Date”), is by and between Merck, Sharp & Dohme Corporation, a corporation organized and existing under the laws of New Jersey (hereinafter referred to as “Merck”), and Targenics, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as “Licensee”). Merck and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 1 TO THE EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • November 22nd, 2017 • ARMO BioSciences, Inc. • Pharmaceutical preparations
THIS Amendment No. 1 to the Exclusive Patent License Agreement (“Amendment No. 1”), dated as of December 12, 2012 (the “Effective Date”), is by and between Merck, Sharpe and Dohme Corporation, a corporation organized and existing under the laws of New Jersey (hereinafter referred to as “Merck”), and Targenics, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as “Licensee”). Merck and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTED Amendment No. 2 to the Exclusive Patent License Agreement between Merck Sharp & Dohme Corp. and ARMO Biosciences Inc.Exclusive Patent License Agreement • November 22nd, 2017 • ARMO BioSciences, Inc. • Pharmaceutical preparations
This Amendment No. 2 (“Amendment”) is entered into as of July 11, 2017 between ARMO BIOSCIENCES INC. (formerly Targenics, Inc.), a corporation organized under the laws Delaware (“Licensee”) and MERCK SHARP & DOHME CORP., a corporation organized under the laws of New Jersey (“MERCK”) to amend the terms of the Exclusive Patent License Agreement between the Parties, effective December 10, 2012, as amended on the same date (the “Agreement”)
